ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved ...

Tendyne is a first-of-its-kind device that offers patients with severe MR a life-saving treatment option, replacing their native mitral valve without open heart surgery to reduce their heart ...

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification Tendyne offers a new ...

There was no evidence of structural valve dysfunction. Their heart failure hospitalization rate improved from 1.3 events per patient per year to 0.6 per patient-year at 1 year and 0.51 at 2 years.

Abbott Laboratories has received approval for a mitral valve replacement that can be implanted without open-heart surgery. The U.S. Food & Drug Administration gave the OK for the North Chicago ...

Abbott Laboratories has reached a deal to pay at least $225 million for Tendyne Holdings Inc., a Roseville-based developer of heart valve technology.

The Tendyne and Cephea valve technologies, like MitraClip, are designed to be implanted in a beating heart without the need for open heart surgery. John M. Capek, Ph.D., Executive Vice President ...

Tendyne is conducting a U.S. clinical trial of a product called the bioprosthetic mitral valve system and it plans to start a study in 2016 to support approval of the device in Europe.

Tendyne officials couldn't be reached for comment Thursday, but investor handouts from the company quote analysts predicting minimally invasive mitral valve replacements will reach $750 million in ...

ABBOTT PARK, Ill., Jan. 30, 2020/ PRNewswire/-- Abbott today announced that its Tendyne™ Transcatheter Mitral Valve Implantation system received CE Mark and is now approved for use in Europe.

ABBOTT PARK, Ill., May 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve ...

ABBOTT PARK, Ill., May 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve ...